G Farsad, MD
General Surgery · Palm Springs, CANPI 1356350805
Payments from drug & device makers
What this record shows
19 manufacturers reported payments, led by Medtronic at 53.9% of the total. Reporting peaked in 2019 at $974 and has fallen 92.4% since, to $74 in 2025.
Across 34 payments — averaging $52.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$953
- Genentech USA, Inc.$122
- Intuitive Surgical$119
- Lilly USA, LLC$117
- Integra Lifesciences Corporation$87
- GE HealthCare$48
- plus $324 from 13 others
What the payments were for
- Travel & lodging$90451%
- Food & beverage$86649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 7 | $953 |
| Genentech USA, Inc. | 1 | $122 |
| Intuitive Surgical | 1 | $119 |
| Lilly USA, LLC | 7 | $117 |
| Integra Lifesciences Corporation | 4 | $87 |
| GE HealthCare | 1 | $48 |
| Edwards Lifesciences | 1 | $34 |
| Taiho Oncology, Inc. | 1 | $33 |
| Sobi, Inc | 1 | $31 |
| Johnson & Johnson | 1 | $29 |
| Organogenesis Inc. | 1 | $29 |
| Polarityte, Inc. | 1 | $27 |
| Incyte Corporation | 1 | $26 |
| AVEO Pharmaceuticals, Inc. | 1 | $24 |
| Dova Pharmaceuticals | 1 | $21 |
| Sanofi | 1 | $19 |
| EMD Serono, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Endurant$848
- TECENTRIQ$122
- Da Vinci Surgical System$119
How this compares
$1,770 in reported general payments places this provider in the 85th percentile of 167 general surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 30 | $386 |
| Cephalexin | 27 | $146 |
| Tramadol Hcl | 25 | $28 |
Paid to pharmacies, not to this prescriber.
Other general surgery in Palm Springs
- Janet IhdePalm Springs$2K
- Peter JamiesonPalm Springs$130
- Daniel SwartzFresno$83K
- Daniel MarcusMarina del Rey$43K
- Brian PalafoxOrange$40K
- Houshmand NaimLos Angeles$33K
- Carlos CorveraSan Francisco$25K
- Stevan ClarkLos Angeles$16K
- Yeong AhnLos Angeles$12K
- Jane KakkisFountain Valley$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.